CH 275 is a peptide analog of somatostatin and binds preferably tosomatostatin receptor1 (sst₁)with aK_iof 52 nM^[1]. CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively^[2]. CH 275 can be used for the research of alzheimer’s disease^[3].

IC50: 30.9 nM; Ki: 52 nM (somatostatin receptor 1)^[1][2]
IC50: 345 nM (somatostatin receptor 3)^[1]

CH275 (100 nM) activates neprilysin activity, wheras treatment with cyclo-SRIF can complete this activation in vitro in primary neuron-based cell culture system, a mixture of wildtype hippocampal, cortical and striatal neuron^[3].

CH275 (osmotic pump administration; 56 μM; two weeks) decreases the level of neprilysin/SRIF in the App knock-in mice^[3].
CH275 directly injects into the Lacunosum molecular layer (Lmol) layer of 2-month-oldApp^NL-G-Fmice for four months.App^NL-G-Fmice begin to exhibit Aβ plaques at two months of age, but CH275 leads to robustly increased the expression of neprilysin in hippocampus which is paralleled by a clear reduction in Aβ plaque load in the same region, and without causing any toxic side effects^[3].

1485.77

C₇₄H₉₆N₁₄O₁₅S₂

174688-78-9

CKFFWXTFTSC (Modifications: Cyclic Cys1-Cys11, X=4-[[(1-methylethyl)amino]methyl]-Phe)

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.